Eli Lilly (LLY) Operating Expenses (2009 - 2026)

Eli Lilly has reported Operating Expenses for 18 years, with the latest figure at $6.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 28.38% year-over-year to $6.7 billion; the trailing twelve-month figure through Mar 2026 stood at $26.4 billion (up 24.48% YoY), and the FY2025 full-year result was $24.9 billion, up 21.86% from the prior year.
• Operating Expenses for Q1 2026 stood at $6.7 billion, down from $7.0 billion in the prior quarter.
• The five-year high for Operating Expenses was $7.0 billion in Q4 2025, with the low at $3.2 billion in Q1 2022.
• Historically, Operating Expenses has averaged $4.9 billion across 5 years, with a median of $4.6 billion in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses retreated 8.43% — and 2025, when it surged 33.69%.
• Eli Lilly's Operating Expenses stood at $3.7 billion in 2022, then rose by 23.89% to $4.6 billion in 2023, then advanced by 27.13% to $5.8 billion in 2024, then climbed by 21.15% to $7.0 billion in 2025, then decreased by 4.19% to $6.7 billion in 2026.
• The last three Operating Expenses figures came in at $6.7 billion (Q1 2026), $7.0 billion (Q4 2025), and $6.6 billion (Q3 2025), per Business Quant data.